DiscussierNovo Nordisk
Novo Nordisk A/S (NYSE: NVO) is a Danish multinational pharmaceutical company and the global leader in diabetes care, commanding approximately one-third of the world's insulin market and pioneering the GLP-1 receptor agonist class with its blockbuster products Ozempic for diabetes and Wegovy for obesity. The company has nearly a century of experience in metabolic disease and has leveraged its deep expertise to become the most valuable company in Europe by market capitalization, as demand for ...